3 results
To evaluate the efficacy and safety of extended release (ER) Niacin/Laropiprant when added to ongoing lipid-modifying therapy in patients with primary hypercholesterolemia or mixed dyslipidemia.
Study IM011-077 is a Phase 2 randomized, open-label, multicenter clinical study designed to assess the safety and tolerability, efficacy and biomarker response of deucravacitinib 6 mg BID (twice daily) in subjects with moderate to severe Ulcerativeā¦
(1) to create and train an algorithm to generate synthetic CT images of the craniofacial area(2) to evaluate the resulting synthetic CT images in terms of geometrical accurate visualization of the craniofacial osseous structures compared to theā¦